PMID- 35308529
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220322
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A 
      Bibliometric Analysis.
PG  - 802036
LID - 10.3389/fmed.2022.802036 [doi]
LID - 802036
AB  - BACKGROUND: Atopic dermatitis (AD) is one of the most common chronic inflammatory 
      skin disorders. Dupilumab, the first targeted biological drug approved for the 
      treatment of AD, has been widely used, along with increasing ocular adverse 
      effects (AEs). OBJECTIVE: To perform a bibliometric analysis of all the qualified 
      literature involving ocular AEs during the treatment of AD with dupilumab. 
      METHODS: Relevant studies were extracted from the Web of Science database and 
      screened by researchers. The bibliographic analysis was performed using the 
      VOSviewer. RESULTS: A total of 138 articles were enrolled in this study. The 
      first study was published in 2016 by Oregon Health and Science University from 
      the United States. The majority of publications were published in the past 3 
      years. British Journal of Dermatology published the highest number of articles. 
      The United States was the country with the most publications. Sanofi (France) and 
      Regeneron Pharmaceuticals (USA) were the leading organizations with the most 
      contributions. Conjunctivitis was the most common ocular AE. The management of AD 
      will continue to be the research hotspot and development trend in this area. The 
      milestone research is the first article "Two Phase 3 Trials of Dupilumab vs. 
      Placebo in Atopic Dermatitis" published in the New England Journal of Medicine. 
      Most of the top 10 papers were mainly randomized, placebo-controlled phase 2 and 
      phase 3 clinical trials and real-life large cohort studies. CONCLUSIONS: This 
      study may help better understand ocular AEs in the dupilumab treatment of AD, and 
      grasp the research trends and most influential topics in this field.
CI  - Copyright (c) 2022 Jia, Qiao, Fang and Zeng.
FAU - Jia, Qian-Nan
AU  - Jia QN
AD  - Department of Dermatology, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, National Clinical Research Center for 
      Dermatologic and Immunologic Diseases, Beijing, China.
FAU - Qiao, Ju
AU  - Qiao J
AD  - Department of Dermatology, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, National Clinical Research Center for 
      Dermatologic and Immunologic Diseases, Beijing, China.
FAU - Fang, Kai
AU  - Fang K
AD  - Department of Dermatology, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, National Clinical Research Center for 
      Dermatologic and Immunologic Diseases, Beijing, China.
FAU - Zeng, Yue-Ping
AU  - Zeng YP
AD  - Department of Dermatology, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, National Clinical Research Center for 
      Dermatologic and Immunologic Diseases, Beijing, China.
LA  - eng
PT  - Systematic Review
DEP - 20220303
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8927737
OTO - NOTNLM
OT  - atopic dermatitis
OT  - bibliometric
OT  - conjunctivitis
OT  - dupilumab
OT  - ocular adverse effects
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/03/22 06:00
MHDA- 2022/03/22 06:01
PMCR- 2022/03/03
CRDT- 2022/03/21 08:40
PHST- 2021/10/26 00:00 [received]
PHST- 2022/01/31 00:00 [accepted]
PHST- 2022/03/21 08:40 [entrez]
PHST- 2022/03/22 06:00 [pubmed]
PHST- 2022/03/22 06:01 [medline]
PHST- 2022/03/03 00:00 [pmc-release]
AID - 10.3389/fmed.2022.802036 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Mar 3;9:802036. doi: 10.3389/fmed.2022.802036. 
      eCollection 2022.